Low frequency of target organ damage in Taiwanese with white coat hypertension

Journal of the Formosan Medical Association

Volumn 104, Issue 5, 2005, Pages 327-332

  Tseng, Yung Zu ^a   Chiang, Fu Tien ^a   Hsu, Kwan Lih ^a   Lo, Huey Ming ^a   Tseng, Chuen Den ^a   Lin, Jiunn Lee ^a   Hwang, Juey Jen ^a   Lai, Ling Ping ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Ambulatory blood pressure monitoring; Blood pressure determination; Left ventricular hypertrophy; Proteinuria; Retinal diseases

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEINURIA; RETINOPATHY; SPHYGMOMANOMETER; TAIWAN; TARGET ORGAN; THORAX RADIOGRAPHY; URINALYSIS; WHITE COAT HYPERTENSION; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; RETINA DISEASE;

ADULT; AGED; BLOOD PRESSURE MONITORING, AMBULATORY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PROTEINURIA; RETINAL DISEASES; TAIWAN;

EID: 24944521676     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Pickering TG, James GD, Boddie C, et al: How common is white coat hypertension? JAMA 1988;259:225-8.
2. White WB, Schulman P, McCabe EJ, et al: Average daily blood pressure, not office blood pressure, determines cardiac function in patients with hypertension. JAMA 1989;261:873-7.
3. Cardillo C, De Felice F, Campia U, et al: Psychophysiological reactivity and cardiac end organ changes in white coat hypertension. Hypertension 1993;21:836-44.
4. Hoegholm A, Kristensen KS, Bang LE, et al: Left ventricular mass and geometry in patients with established hypertension and white coat hypertension. Am J Hypertens 1993;6:282-6.
5. Cuspidi C, Marabini M, Lonati L, et al: Cardiac and carotid structure in patients with established hypertension and white-coat hypertension. J Hypertens 1995;13:1707-11.
6. Ferrara LA, Guida L, Pasanisi F, et al: Isolated office hypertension and end-organ damage. J Hypertens 1997;15:979-85.
7. Kario K, Shimada K, Schwartz JE, et al: Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Cardiol 2002;39:52-4. [In Japanese; English abstract].
8. Boone JL: Stress and hypertension. In: Boone JL, ed. Primary care. Vol. 18. Clinics in office practice. Philadelphia: WB Saunders; 1991:623-50.
9. Gosse P, Promax H, Durandet P, et al: "White coat" hypertension. No harm for the heart. Hypertension 1993;22:766-70.
10. Hoegholm A, Bang LE, Kristensen KS, et al: Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. Hypertension 1994;24: 101-5.
11. Verdecchia P, Schillaci G, Borgioni C, et al: White coat hypertension and white coat effect. Similarities and differences. Am J Hypertens 1995;8:790-8.
12. Kario K, Matsuo T, Kobayashi H, et al: Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. Arterioscler Thromb Vasc Biol 1996;16:455-61.
13. Hoegholm A, Kristensen KS, Bang LE, et al: White coat hypertension and target organ involvement: the impact of different cut-off levels on albuminuria and left ventricular mass and geometry. J Hum Hypertens 1998;12:433-9.
14. Pierdomenico SD, Costantini F, Bucci A, et al: Low-density lipoprotein oxidation and vitamins E and C in sustained and white-coat hypertension. Hypertension 1998;31:621-6.
15. Soma J, Aakhus S, Dahl K, et al: Hemodynamics in white coat hypertension compared to ambulatory hypertension and normotension. Am J Hypertens 1996;9:1090-8.
16. Glen SK, Elliott ML, Curzio JL, et al: White coat hypertension as a cause of cardiovascular dysfunction. Lancet 1996;348: 654-7.
17. Kuwajima I, Suzuki Y, Fujisawa A, et al: Is white coat hypertension innocent? Structure and function of the heart in the elderly. Hypertension 1993;22:826-31.
18. Lue BH, Hsu KL, Tseng YZ: Cardiac end-organ changes: comparison between white coat hypertension and persistent mild hypertension. J Formos Med Assoc 1996;95:440-5.
19. Sega R, Trocino G, Lanzarotti A, et al: Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation 2001;104:1385-92.
20. Grandi AM, Broggi R, Colombo S, et al: Left ventricular changes in isolated office hypertension: a blood pressure-matched comparison with normotension and sustained hypertension. Arch Intern Med 2001;161:2677-81.
21. Verdecchia P, Schillaci G, Boldrini F, et al: Variability between current definitions of "normal" ambulatory blood pressure. Implications in the assessment of white coat hypertension. Hypertension 1992;20:555-62.
22. Rizzo V, Cicconetti P, Bianchi A, et al: White-coat hypertension and cardiac organ damage in elderly subjects. J Hum Hypertens 1996;10:293-8.
23. Palatini P, Mormino P, Santonastaso M, et al: Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: results from the HARVEST study. Hypertension 1998;31:57-63.
24. Muscholl MW, Hense HW, Brockel U, et al: Changes in left ventricular structure and function in patients with white coat hypertension: cross sectional survey. BMJ 1998;317:565-70.
25. Bar J, Maymom R, Padoa A, et al: White coat hypertension and pregnancy outcome. J Hum Hypertens 1999;13:541-5.
26. Pickering TG, Levenstein M, Walmsley P: Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender and presence of white coat hypertension. Results of HALT study. Am J Hypertens 1994;7:848-52.
27. Waeber B, Heynen G, Bruner HR: Analysis of ambulatory blood pressure monitoring: the problem of white coat hypertension. Responders and no responders. Blood Press Monit 1996;1: 289-91.
28. Pickering TG: White coat hypertension. In: Waeber B, O'Brien E, O'Malley K, eds. Twenty-four-hour ambulatory blood pressure monitoring in clinical practice. New York: Raven Press; 1994:33-45.
29. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
30. Drayer JIM, Weber MA, DeYoung JL, et al: Circadian blood pressure patterns in ambulatory hypertensive patients. Am J Med 1982;93:493-9.
31. Kannel WB, Gordon T, Offutt D: Left ventricular hypertrophy by electrocardiogram, prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 1969;71:89-105.
32. Sokolow M, Lyon TP: The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949;37:161-86.
33. Romhilt DW, Estes EH Jr: A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am Heart J 1968;75: 752-8.
34. Ungerleider HE, Gubner R: Evaluation of heart size measurements. Am Heart J 1942;24:494-510.
35. Keith NM, Wagener HP, Barker NW: Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1974;268:336-45.
36. Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet 1998;352:1801-7.
37. MacMahon S, Peto R, Cutler J, et al: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
38. Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-8.
39. Hoegholm A, Kristensen KS, Madsen NH, et al: White coat hypertension diagnosed by 24-h ambulatory monitoring. Examination of 159 newly diagnosed hypertensive patients. Am J Hypertens 1992;5:64-70.
40. Burnier M, Biollaz J, Magnin JL, et al: Renal sodium handing in patients with untreated hypertension and white coat hypertension. Hypertension 1994;23:496-502.
41. Bjorklund K, Lind L, Vessby B, et al: Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period: a population-based study of elderly men. Circulation 2002;106:63-8.
42. Pierdomenico SD, Lapenna D, Guglielmi MD, et al: Target organ status and serum lipids in patients with white coat hypertension. Hypertension 1995;26:801-7.
43. Pose-Reino A, Gonzalez-Juanatey JR, Pastor C, et al: Clinical implications of white coat hypertension. Blood Press 1996;5: 264-73.
44. Pickering TG: White coat hypertension. Curr Opin Nephrol Hypertens 1996;5:192-8.
45. Chrysant SG: Treatment of white coat hypertension. Curr Hypertens Rep 2000;2:412-7.
46. Okin PM, Roman MJ, Devereux RB, et al: Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995;25:417-23.
47. Okin PM, Roman MJ, Devereux RB, et al: Electrocardiographic identification of left ventricular hypertrophy: test performance in relation to definition of hypertrophy and presence of obesity. J Am Coll Cardiol 1966;27:124-31.
48. Dahlöf B, Devereux RB, de Faire U, et al: The losartan intervention for endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997;10:705-13.
49. Devereux RB, Bella J, Boman K, et al: Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press 2001;10:74-82.